Abstract: Neoadjuvant chemotherapy (NAC) in women with large breast tumours can downsize tumours to allow for breast conservation surgery (BCs). The aim of this study is to compare the BCs rate between those who had NAC versus those who underwent surgery first and to determine the factors affecting response rate. 1,183 patients, who had surgery for breast cancer in a single institution from December 2012 to December 2015, were included in this study. 80 (6.8%) patients had NAC. Patient and tumours characteristics, and type of surgery were compared between those who had surgery first or surgery after NAC. Variables affecting the response rate were analyzed. The BCS rate between the surgery first and the NAC group were similar (34.2% versus 35%). The pathological complete response (PCr) rate, partial response rate and stable disease rate were 22.5%, 65% and 12.5%, respectively. PCR rate was not significantly affected by subtype of breast cancer, although there was a tendency for PCr to be higher in er-negative (32.4%), Pr-negative (26.1%) Her2-positive (28.6%), Her2-overexpressing (37.5%) and TNBC (22.7%) tumours. NAC is able to downsize tumour to achieve BCs rate that is similar to those without NAC. 
Introduction
In a low-and middle-income country such as Malaysia, breast cancer presents typically with a large lump where mastectomy is required. A recent review of breast cancer in Malaysia showed that the mean size at presentation is around 4.5 cm, and over 50% of women present with stages 3 and 4 breast cancer [1] . Neoadjuvant chemotherapy (NAC) in women presenting with large operable breast tumours can downsize tumour to allow for breast conservation surgery (BCs) [2] and allow for surgery to be carried out in women with inoperable locally advanced tumours [3] . NAC also has the advantage of determining tumour chemosensitivity [4] .
A complete pathological response rate (PCr) is associated with better survival and hence can be used as a prognostic indicator [5] .
Despite all these obvious advantages of NAC, in most settings, surgery first is still carried out as long as the tumour is deemed operable, and NAC is reserved for those with large inoperable tumours and in stage 4 breast cancer, where chemotherapy should really be called primary chemotherapy rather than NAC. surgery in stage 4 breast cancer, after response to chemotherapy, has shown no benefit to survival in a prospective trial [6] , although several retrospective studies have shown improvement in duration of survival when surgery is carried out. The primary objective of this study is to compare the BCs rate between those who had NAC versus those who underwent surgery first. The secondary objective is to determine the factors affecting response rate from NAC in 60 doi: 10.18282/amor.v3.is1.197 women with breast cancer.
Materials and methods
1,183 patients who had surgery (either mastectomy or breast conserving surgery) for breast cancer in subang Jaya Medical Centre (sJMC) from December 2012 to December 2015 were included in this study after exclusion of ductal carcinoma in situ (DCIs) and non-epithelial cancers. The data was retrieved from the sJMC Database, where the data is prospectively collected. sJMC is a private hospital in an affluent urban area, where majority of the patients have private health insurance. Patients' age, ethnicity, tumour size, stage, grade, estrogen (er) and progesterone receptor (Pr) status, human epidermal growth factor-2 receptor (Her2) status and type of surgery (BCs versus mastectomy) were compared between the two groups, i.e., surgery first or NAC. ER, PR and HER2 were assessed by immunohistochemistry, and silver In Situ Hybridization (sIsH) for Her2 was carried out if reported as 2+ or equivocal. Immunohistochemical analysis for estrogen receptor was performed using a monoclonal rabbit antihuman estrogen receptor α (Clone eP1, DAKO) and progesterone receptor was assayed using CONFIrM anti-Pr (1e2, Ventana). The tests were performed on the Ventana Ultra platform using OptiView Detection assay. er and Pr are considered positive if more than 1% of cells stain positive. Her2 is considered positive if reported as 3+ by HercepTest or over-expressed by sIsH. Of the total number of patients, 80 (6.8%) patients had NAC before surgery. The response rate assessments are namely: 1) PCr, defined as absence of invasive carcinoma or ductal carcinoma in situ alone; 2) partial response (Pr), defined as reduction of >50% of the initial tumour size; 3) stable disease (SD), defined as a reduction of <50% of the original tumour size; and 4) progressive disease (PD), defined as an increase in the tumour size. Variables affecting the response rate were analysed in these 80 patients using Chi-square test.
Ethics statement
The sJMC Breast Cancer Database is approved by the Institutional ethics review Board.
Results
Compared to those undergoing surgery first, patients who had chemotherapy first were significantly more likely to be Malay, younger age (median age of 43 years versus 51 years) with larger tumour size (median size: 8 cm versus 2 cm), er-and Pr-negative, and more advanced stage of cancer. Triple-negative breast cancers were also more likely to have neoadjuvant chemotherapy rather than surgery first. However, the breast conservation rates between the two groups were similar (34.2% in the mastectomy group versus 35% in the NAC group) ( Table 1 ). All the patients in the NAC group would have required a mastectomy because of the size of the tumour. It is interesting to note that only 4 out of 440 (0.9%) patients with stage 2 breast cancer had NAC, and this was because the patients did not want a mastectomy and all these four patients were successfully converted to BCs.
90% of the women in the NAC group received thirdgeneration regimes (anthracycline and taxanes). Of the 28 patients who were Her2-positive, 17 (60.7%) received Herceptin, of whom 6 (35.3%) had a complete pathological response (PCr). Although all patients in the NAC group had initial enlarged axillary lymph nodes clinically, 48.8% of them were node-negative at surgery. The PCr, Pr and sD/PD rates were 22.5%, 65% and 12.5%, respectively. Only one patient had progressive disease, and this was analysed together with the sD group. PCr rate was not significantly affected by age, grade, er, Pr, Her2 or subtype of breast cancer, although there was a tendency for PCr to be higher in er-negative (32.4%), Pr-negative (26.1%), Her2-positive (28.6%), Her2-overexpressing (37.5%) and triple-negative breast cancer (TNBC) (22.7%) tumours ( Table 2) .
Discussion
It is well accepted that chemotherapy, whether given in the adjuvant or neo-adjuvant setting, lead to comparable longterm survival. Besides reducing the size of the tumour at presentation, NAC offers an opportunity to determine if the tumour is sensitive to the chemotherapeutic agents used, and this cannot be assessed in the adjuvant setting, where the tumour is already removed. It also gives an opportunity to investigate the effectiveness of new systemic therapeutic agents, as well as offering an opportunity for translational studies to develop and validate predictive biomarkers. In addition, pathologically complete response might be a surrogate for better survival [7] .
The National surgical Adjuvant Breast and Bowel Project (NsABP) B-18 study on four cycles of AC (Adriamycin and Cyclophosphamide) as NAC was shown to achieve a PCr of 13.7% [8] . Addition of four cycles of docetaxel to four cycles of AC in the NsABP B-27 study was able to improve the PCr rate to about 26.1% [9] . For patients with Her2-overexpressing tumours who received trastuzumab together with NAC, a PCr rate of over 39% has been reported [10] . In this study, 90% had anthracyclines and taxanes, while only eight had anthracyclines alone, and the overall PCr rate of 22.1% is consistent with reported PCr rates. Not all of the 28 Her2-positive patients had access to Herceptin because of the cost, but of the 16 who had neoadjuvant Herceptin, the PCr rate was 35.3%, which was again similar to that in the reported studies.
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Although there may be differences in the definition of PCR, the majority of studies used the definition as no residual invasive cancer in the breast or lymph nodes. Besides the type of chemotherapeutic agent that might influence the PCR rate, the type of breast cancer is also an important factor. The largest benefit is seen in those patients who are younger and with smaller tumour size and higher grade, triple-negative breast cancer, as well as Her2 overexpressed [11] . In the current study, only the smaller size was significantly associated with an increased PCr rate. Although there was a tendency for Her2 over-expressing and triple-negative breast cancer to show a higher PCr rate, this did not reach a significant value. A study to assess the molecular subtypes determined by hormone receptors (Hr), Her2 status and the role of proliferation as measured by the Ki-67 marker as predictive and prognostic factors in breast cancer treatment treated with NAC (anthracycline and taxanes) with or without trastuzumab according to Her2 status showed that the PCr rate was 9% in Hr+/Her2-, 23% in Hr+/Her2+, 50% in Hr-/Her2+ and 56% in Hr-/Her2-. The PCr rate was also significantly higher in patients that had high Ki-67 of ≥20% [12] .
There may be other biomarkers which can be used to predict response to different types of chemotherapy. A retrospective study of neoadjuvant chemotherapy identified 12 women with BRCA1 mutation that was treated with cisplatin and 10 of these patients had a PCr [13] . However, this has not been tested in a prospective trial. With all the advantages of NAC, in the real-world setting in Malaysia, it is still very much reserved for stage 3 cancers and, as in this study, with a median size of 8 cm. In Malaysia, most breast cancers are initially seen by the surgeon. With only 40 breast surgeons for a population of 30 million, the majority of patients, especially in the periphery, are seen by general surgeons. since there is also a shortage of oncologists, wherever possible, surgery is carried out first in Stage 1, Stage 2 and operable Stage 3 cancers. However, the current study is carried out in a tertiary private hospital under a single breast surgeon with very good oncology support. Why then is the neoadjuvant chemotherapy rate only 6% overall, with 0.9% in stage 2 and 22.5% stage 3? The reason is that most women are more fearful of chemotherapy than of surgery, so when offered the choice of neoadjuvant chemotherapy, they would often choose surgery first, even if it means a mastectomy.
Once the decision for NAC is made, it is important that the cancer is tested for er, Pr, Her2 and Ki-67, as these may influence the decision-making in operable large tumours. since studies have shown that hormone receptor positive tumours may not respond very well to NAC, surgery first in such tumours will be more appropriate. It is also seen in this study that besides having a large tumour, women with negative hormone receptors and triple-negative breast cancer were significantly more likely to be offered neoadjuvant chemotherapy. In this study, before a patient undergoes neoadjuvant chemotherapy, the hormone receptors and Her2 status is assessed. Ki-67 was 63 not routinely done, and has not been used for decisionmaking in this study. It is also important to place a clip under ultrasound in the centre of the tumour, in case there is a complete clinical response and there is no palpable tumour for BCs. The tumour size needs to be checked clinically or by ultrasound to determine the response. If there is no response or progression, a change in the type of chemotherapeutic agent may be needed, or a mastectomy carried out if operable, even if a flap is required for skin closure. If there is a good response to NAC, the decision for BCs or mastectomy will follow the same principles as for patients undergoing primary surgery, the most important of which is that the disease should not be multifocal. In the NsABP B-18 study, which is on NAC in operable breast cancer, the BCs rate increased from 60% in the primary surgery group to 68% in the NAC group, with no significant difference in the local recurrence rate [14] . In the current study, there was no difference in the BCS rate between the surgery first or the NAC group (34.2% versus 35%, respectively); however, it is noted that the patients in the NAC group had a median size of 8 cm, and all would have required a mastectomy.
Conclusion
Neoadjuvant chemotherapy is able to downsize tumour to achieve breast conservation rate that is similar to those without neoadjuvant chemotherapy. The PCr rate is not significantly affected by the breast cancer subtypes, although there is a tendency for er-negative, Pr-negative and Her2 overexpressing tumour to achieve a higher PCr rate. A longer follow-up is required to determine the survival outcome in the two groups.
